Quality and Regulatory Sourcebook March 2022
Read the article:
A New Route to Pharma GDP Compliance and Standardization
Read the eBook:
BioPharm International's Quality and Regulatory Sourcebook eBook
A New Route to Pharma GDP Compliance and Standardization
Publication
Article
BioPharm InternationalBioPharm International, Regulatory Sourcebook March 2022
Volume 2022 eBook
Issue 1
Pages: 24-29
A consensus-based approach to GDP lies at the heart of a new industry-wide program seeking to rationalize, standardize, and harmonize the adherence to pharma transportation norms and regulatory guidelines.
FABIAN - STOCK.ADOBE.COM
The logistics associated with the safe and efficient physical transportation of pharmaceuticals is increasingly taxing the minds of logisticians as medicines become more complex and labile and their regulatory oversight intensifies. The statutory need to maintain the therapeutic and physical integrity of drugs during transit renders the management of quality and the adherence to good distribution practice (GDP) guidelines an absolutely critical part of the pharmaceutical supply process.
Read this article in Pharmaceutical Technology’s March 2022 Quality and Regulatory Sourcebook eBook.
About the author
Courtney Soulsby is sector director, Healthcare & Life Sciences, BSI.
Alan Kennedy is director, Team Poseidon.
Article Details
BioPharm International eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 24–29
Citation
When referring to this article, please cite it as C. Soulsby, A. Kennedy, “A New Route to Pharma GDP Compliance and Standardization," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).
Articles in this issue
In-Use Testing of Cleanroom Garments
How a Lack of Critical Thinking is Hindering Regulatory Compliance
Contextualizing Computer Validation
Assessing the Quality of CAR-T Cells Using ddPCR
The Data Relationship
Supply Chain Considerations for Ensuring Quality
DSCSA’s Next Big Hurdle
A New Route to Pharma GDP Compliance and Standardization
Remote Inspections - Lessons Learned
Recent Videos
Related Content
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025Article
The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
